# Signals Article: Putative Target P08519 for Atherosclerosis Lp(a)
Background
Atherosclerosis is a chronic cardiovascular condition characterized by the buildup of plaques in the arterial walls, leading to reduced blood flow and increased risk of cardiovascular events. Lipoprotein(a), or Lp(a), is a known risk factor for atherosclerosis, with elevated levels associated with an increased risk of cardiovascular diseases. Identifying molecular targets related to Lp(a) could provide new avenues for therapeutic intervention in atherosclerosis.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P08519 was identified as a putative target for atherosclerosis associated with Lp(a). This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200077263, GDS:200066570, GDS:200066569, GDS:200066568, and GDS:200038120. Although P08519 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing P08519 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P08519's potential as a target for atherosclerosis. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P08519 as a target for atherosclerosis associated with Lp(a), several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of atherosclerosis. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P08519. If validated, assessing the druggability of P08519 via DGIdb and ChEMBL will be crucial for potential therapeutic development.